EUVIMEDEUVIMED entdecken
Crossref

CXCL12 upregulates PD-L1 expression and promotes M2 polarisation of tumour-associated macrophages to confer anti-PD-1 resistance in gastric cancer

Chao Wu, Boya Li, Huiling Li, Panjie Zhu, Yichen Wang, Xiaoxi Li, Yingnan Feng, Li Zhang, Zizhao Cheng, Dan Gao, Lan Zhang, Xianzhe Dong

Gastric Cancer · 2026

DOI: 10.1007/s10120-026-01769-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastric Cancer, 2026. Verfasst von Chao Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xuanwu Hospital of Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China. Hauptthemen laut MEDLINE: Chemokine CXCL12, Stomach Neoplasms, Tumor-Associated Macrophages, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Talent Project established by Chinese Pharmaceutical Association Hospital Pharmacy department, Beijing Hospitals Authority Youth Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Immunotherapy offers promise for gastric cancer (GC) patients, yet its efficacy is substantially limited by high rates of treatment resistance, the mechanisms of which remain incompletely characterised. We aimed to delineate the role and mechanistic basis of CXCL12 in conferring anti-PD-1 resistance in GC.

Methods

An anti-PD-1-resistant GC mouse model was established through chronic anti-PD-1 induction and in vivo tumour tissue passaging. Human and murine GC cell lines stably overexpressing CXCL12 (OE-CXCL12) were generated via lentiviral transduction to construct corresponding OE-CXCL12 GC mouse models. Single-cell transcriptomics analysed the tumour microenvironment (TME) in anti-PD-1-resistant GC. Molecular docking and Drug Affinity Responsive Target Stability (DARTS) assays predicted and validated ligand-receptor binding, respectively. RNA or protein expression of specific molecules was quantified by RT-qPCR, ELISA, immunofluorescence, and western blotting.

Results

Anti-PD-1-resistant GC models showed upregulated CXCL12, PD-L1, and CD206 expression with unchanged PD-1. OE-CXCL12 reduced anti-PD-1 sensitivity, elevated M2-TAM infiltration and TGF-β, IL-10, IL-4 levels in TME, reduced M1-TAM and CD8⁺ T cell infiltration and IL-12 level, with differentially expressed genes enriched in HIF-1, PD-L1/PD-1 checkpoint, and PI3K/AKT signalling pathways. M2-TAM-conditioned medium elevated SOX2, OCT-4, NANOG in GC cells. Mechanistically, CXCL12 binds CXCR4 to activate PI3K/AKT/HIF-1α, promoting PD-L1 expression and M2-TAM polarisation. CXCL12 inhibition recovered anti-PD-1 efficacy.

Conclusions

This identifies CXCL12 as a novel anti-PD-1 resistance gene in GC, with the CXCL12/CXCR4/PI3K/AKT/HIF-1α axis induces anti-PD-1 tolerance through a dual-pathway mechanism of promoting PD-L1 expression and M2-TAM polarisation, providing potential therapeutic strategies to prevent and reverse anti-PD-1 resistance in GC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemokine CXCL12Stomach NeoplasmsTumor-Associated MacrophagesDrug Resistance, NeoplasmB7-H1 AntigenImmune Checkpoint InhibitorsAnimalsHumansMiceTumor MicroenvironmentUp-RegulationCell Line, TumorProgrammed Cell Death 1 ReceptorGene Expression Regulation, NeoplasticSignal Transduction

Stichwörter der Autor:innen

CXCL12Gastric cancerImmunotherapyPD-1Tumor associated macrophages

Substanzen

Chemokine CXCL12B7-H1 AntigenCXCL12 protein, humanCD274 protein, humanProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsCxcl12 protein, mouse

Autor:innen und Institutionen

  • Department of Pharmacy, Xuanwu Hospital of Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China.
  • Beijing Municipal Geriatric Medical Research Center, Beijing, 100053, China.
  • School of Pharmacy, Zunyi Medical University, Guizhou, 563006, China.
  • Department of Clinical Pharmacology, Chinese PLA General Hospital, Beijing, 100141, China.
  • Department of Pharmacy, Xuanwu Hospital of Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China. zhanglan@xwhosp.org.
  • Department of Pharmacy, Xuanwu Hospital of Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China. dongxianzhe@xwhosp.org.

Förderung

  • National Natural Science Foundation of China
  • Talent Project established by Chinese Pharmaceutical Association Hospital Pharmacy department
  • Beijing Hospitals Authority Youth Programme
  • Youth Programme of Xuanwu Hospital of Capital Medical University
  • Youth Program of Beijing Municipal TCM Science and Technology Development Fund

Zitieren

APA

Wu, C., Li, B., Li, H., Zhu, P., Wang, Y., Li, X., Feng, Y., Zhang, L., Cheng, Z., Gao, D., Zhang, L., & Dong, X. (2026). CXCL12 upregulates PD-L1 expression and promotes M2 polarisation of tumour-associated macrophages to confer anti-PD-1 resistance in gastric cancer. Gastric Cancer. https://doi.org/10.1007/s10120-026-01769-0

Vancouver

Wu C, Li B, Li H, Zhu P, Wang Y, Li X, et al. CXCL12 upregulates PD-L1 expression and promotes M2 polarisation of tumour-associated macrophages to confer anti-PD-1 resistance in gastric cancer. Gastric Cancer. 2026. doi:10.1007/s10120-026-01769-0

BibTeX
@article{Wu2026,
  author = {Wu, Chao and Li, Boya and Li, Huiling and Zhu, Panjie and Wang, Yichen and Li, Xiaoxi and Feng, Yingnan and Zhang, Li and Cheng, Zizhao and Gao, Dan and Zhang, Lan and Dong, Xianzhe},
  title = {CXCL12 upregulates PD-L1 expression and promotes M2 polarisation of tumour-associated macrophages to confer anti-PD-1 resistance in gastric cancer},
  journal = {Gastric Cancer},
  year = {2026},
  doi = {10.1007/s10120-026-01769-0}
}
Kostenlos starten →